Royalty Report: Drugs, Central Nervous System – Collection: 215874


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Central Nervous System

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 215874

License Grant
Licensee has in-licensed the rights to use the Licensor patents with drugs that like carbamazepine are voltage-gated sodium channel blockers in North America.
License Property
Carbamazepine is used to prevent and control seizures. This medication is known as an anticonvulsant or anti-epileptic drug. It is also used to relieve certain types of nerve pain (such as trigeminal neuralgia). This medication works by reducing the spread of seizure activity in the brain and restoring the normal balance of nerve activity.
Field of Use
The license field includes Sodium-voltage gated channels inhibitors and blockers for the treatment of epilepsy, neuropathic pain, and bipolar disorder.

IPSCIO Record ID: 344504

License Grant
The Licensor of Portugal grants an exclusive license under the Licensor Patents and Know-How to use, market, distribute, import, commercialize, offer for sale and sell the Licensed Products under the Licensor Trademarks within the Field and Territory either directly on its own and/or through its permitted Affiliates, sublicensee and/or distributors.

Licensor grants an exclusive license to use the Licensor Trademarks in connection with any Licensed Products that Licensee uses, markets, promotes, distributes, imports, commercializes, offers for sale or sells within the Field and Territory either directly on its own and/or through its Affiliates, sublicensee, and/or distributors.

Licensor grants a non-exclusive license to use the Licensor Logo on all packaging materials, promotional materials and documents that are used by Licensee either directly on its own and/or through its sublicensee, contractors or distributors in connection with the development, promotion, marketing, offer for sale, sale, import and commercialization of the Licensed Products.

Licensor grants a worldwide, non-exclusive license, without any right to sub-license, under the Licensor Patents and Licensor Know-How to develop or have developed on its behalf, Licensed Products for use and sale within the Field and the Territory,

License Property
Licensor Controls the Licensor Patents and Licensor Know-How relating to its proprietary compound xxx 2-093 and its use in the treatment of human diseases and conditions including, without limitation, epilepsy;

Licensed Products means the xxx 2-093 Product and all other products, including any current or future dosages, formulations, improvements and/or delivery modes comprising xxx 2-093 and all possible metabolites, salts, hydrates, polymorphs, crystalline forms, solvates and prodrugs thereof, including any present and future combination products containing xxx 2-093 or a metabolite, salt, hydrate, polymorph, crystalline form, solvate or prodrug thereof, as one of the active ingredients.

xxx 2-093 means Licensors proprietary compound (S)-(-)-10-acetoxy-10,11- dihydro-SH-dibenz/b,f/azepine-5-carboxamide, known under the International Nonproprietary Name (INN) Eslicarbazepine Acetate.

Licensor Trademarks mean ERELIB' and PAZZUL.

The logo is BIAL.

Field of Use
The license is for the anti-epileptic compound, BIA 2-093, which we now refer to as SEP-0002093.

SEP-0002093 is a new chemical entity which is intended to offer patients suffering with partial epilepsy additional control of their seizures and improved quality of life. Licensor has completed a Phase III program in Europe for the adjunctive treatment of epilepsy.

The Field means all human and non-human diagnostic, prophylactic and therapeutic uses of the Licensed Products for adjunctive use in Adult Partial Epileptic Seizures and any and all new indications, including but not limited to Epilepsy Monotherapy, Trigeminal Neuralgia, Diabetic Neuropathic Pain and Post-herpetic Neuralgia.

IPSCIO Record ID: 343475

License Grant
Licensee secured global rights from Licensor to develop and commercialize the investigational medicine soticlestat (TAK-935/OV935).
License Property
Soticlestat (TAK-935/OV935) is a potent, highly selective, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H), with the potential to reduce seizure susceptibility and improve seizure control. CH24H is predominantly expressed in the brain, where it converts cholesterol into 24S-hydroxycholesterol (24HC) to adjust the homeostatic balance of brain cholesterol. 24HC is a positive allosteric modulator of the NMDA receptor and modulates glutamatergic signaling associated with epilepsy. Glutamate is one of the main neurotransmitters in the brain and has been shown to play a role in the initiation and spread of seizure activity. Recent literature indicates that CH24H is involved in over-activation of the glutamatergic pathway through modulation of the NMDA channel and that increased expression of CH24H can disrupt the reuptake of glutamate by astrocytes, resulting in epileptogenesis and neurotoxicity. Inhibition of CH24H by soticlestat reduces the neuronal levels of 24HC and may improve distorted excitatory/inhibitory balance in the brain.
Field of Use
Field of use is for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome and Lennox-Gastaut syndrome.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.